PT  - JOURNAL ARTICLE
AU  - Vinall, Maria
ED  - van der Heijde, Désirée
TI  - The RANKL Inhibitor Denosumab Reduces Progression of the Total Sharp Score and Bone Erosions in Patients with Rheumatoid Arthritis
DP  - 2007 Sep 01
TA  - MD Conference Express
PG  - 14--15
VI  - 7
IP  - 4
4099  - http://mdc.sagepub.com/content/7/4/14.2.short
4100  - http://mdc.sagepub.com/content/7/4/14.2.full
AB  - Denosumab is a fully human monoclonal antibody that binds to and inhibits RANK Ligand (RANKL), a key mediator of osteoclast formation, function, and survival. This article discusses an ongoing, double-blind, placebo-controlled, phase 2 study was conducted to determine if denosumab treatment could reduce the progression of bone erosions in patients with RA who were on background methotrexate.